Autoimmune Liver Diseases in Systemic Rheumatic Diseases

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2022 Aug 11

PMID 35949355

Authors

Chrong-Reen Wang

Hung-Wen Tsai

Affiliations

Soon will be listed here.

Abstract

Systemic rheumatic diseases (SRDs) are chronic, inflammatory, autoimmune disorders with the presence of autoantibodies that may affect any organ or system. Liver dysfunction in SRDs can be associated with prescribed drugs, viral hepatitis, alternative hepatic comorbidities and coexisting autoimmune liver diseases (AILDs), requiring an exclusion of secondary conditions before considering liver involvement. The patterns of overlap diseases depend predominantly on genetic determinants with common susceptible loci widely distributing in both disorders. In AILDs, it is important to identify the overlapping SRDs at an early stage since such a coexistence may influence the disease course and prognosis. Commonly co-occurring SRDs in AILDs are Sjögren syndrome (SS), rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) in autoimmune hepatitis (AIH), and SS, RA or systemic sclerosis in primary biliary cholangitis. Owing to different disease complications and therapies, it is imperative to differentiate between SLE liver involvement and SLE-AIH overlap disease. Therapeutic options can be personalized to control coexisting conditions of liver autoimmunity and rheumatic manifestations in AILD-SRD overlap diseases. The collaboration between hepatologists and rheumatologists can lead to significant advances in managing such a complex scenario. In this review, we provide a comprehensive overview on coexisting AILDs in different SRDs and the therapeutic approach in managing these overlap diseases.

Citing Articles

Clinical and laboratory characteristics of Sjögren's syndrome-associated autoimmune liver disease: a real-world, 10-year retrospective study.

Liang P, Huang Y, Hu Z, Zhou L, Cai S, Zhong J Clin Rheumatol. 2025; 44(3):1225-1236.

PMID: 39826046 DOI: 10.1007/s10067-024-07273-z.

Autoimmune hepatitis: Towards a personalized treatment.

Costaguta A, Costaguta G, Alvarez F World J Hepatol. 2024; 16(11):1225-1242.

PMID: 39606175 PMC: 11586748. DOI: 10.4254/wjh.v16.i11.1225.

Rare co-occurrence of probable pernicious anemia and autoimmune hepatitis in a 55-year-old male patient: A case report.

Ibrahim Siddiqui A, Luqman M, Mustafa Siddiqui A, Bin Aijaz A, Zuberi M, Rauf S SAGE Open Med Case Rep. 2024; 12:2050313X241290382.

PMID: 39524493 PMC: 11544675. DOI: 10.1177/2050313X241290382.

Primary biliary cholangitis has causal effects on systemic rheumatic diseases: a Mendelian randomization study.

Zhang H, Zhou Z, Chen K, Xiong L, Wu J, Jin L BMC Gastroenterol. 2024; 24(1):294.

PMID: 39210292 PMC: 11360496. DOI: 10.1186/s12876-024-03319-3.

Rosacea and autoimmune liver diseases: a two-sample Mendelian randomization study.

Wu W, Tong H, Li Y, Cui J Arch Dermatol Res. 2024; 316(8):549.

PMID: 39162878 PMC: 11335937. DOI: 10.1007/s00403-024-03331-3.

References

Tsokos G . Systemic lupus erythematosus. N Engl J Med. 2011; 365(22):2110-21. DOI: 10.1056/NEJMra1100359. View

Wong G, Yeong T, Lawrence D, Yeoman A, Verma S, Heneghan M . Concurrent extrahepatic autoimmunity in autoimmune hepatitis: implications for diagnosis, clinical course and long-term outcomes. Liver Int. 2016; 37(3):449-457. DOI: 10.1111/liv.13236. View

Rajoriya N, Wotton C, Yeates D, Travis S, Goldacre M . Immune-mediated and chronic inflammatory disease in people with sarcoidosis: disease associations in a large UK database. Postgrad Med J. 2009; 85(1003):233-7. DOI: 10.1136/pgmj.2008.067769. View

Han J, Wang S, Kwong T, Liu J . Dermatomyositis as an extrahepatic manifestation of hepatitis B virus-related hepatocellular carcinoma: A case report and literature review. Medicine (Baltimore). 2018; 97(33):e11586. PMC: 6113031. DOI: 10.1097/MD.0000000000011586. View

Mackay I, TAFT L, COWLING D . Lupoid hepatitis and the hepatic lesions of systemic lupus erythematosus. Lancet. 1959; 1(7063):65-9. DOI: 10.1016/s0140-6736(59)91136-5. View

Iwadate H, Ohira H, Saito H, Takahashi A, Rai T, Takiguchi J . A case of primary biliary cirrhosis complicated by Behçet's disease and palmoplantar pustulosis. World J Gastroenterol. 2006; 12(13):2136-8. PMC: 4087700. DOI: 10.3748/wjg.v12.i13.2136. View

Yazici Y, Hatemi G, Bodaghi B, Cheon J, Suzuki N, Ambrose N . Behçet syndrome. Nat Rev Dis Primers. 2021; 7(1):67. DOI: 10.1038/s41572-021-00301-1. View

Watt F, James O, Jones D . Patterns of autoimmunity in primary biliary cirrhosis patients and their families: a population-based cohort study. QJM. 2004; 97(7):397-406. DOI: 10.1093/qjmed/hch078. View

Ramos-Casals M, Brito-Zeron P, Soto M, Cuadrado M, Khamashta M . Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol. 2008; 22(5):847-61. DOI: 10.1016/j.berh.2008.09.008. View

10.

Matsumoto T, Kobayashi S, Shimizu H, Nakajima M, Watanabe S, Kitami N . The liver in collagen diseases: pathologic study of 160 cases with particular reference to hepatic arteritis, primary biliary cirrhosis, autoimmune hepatitis and nodular regenerative hyperplasia of the liver. Liver. 2000; 20(5):366-73. DOI: 10.1034/j.1600-0676.2000.020005366.x. View

11.

Sanjeevaiah A, Kerr T, Beg M . Approach and management of checkpoint inhibitor-related immune hepatitis. J Gastrointest Oncol. 2018; 9(1):220-224. PMC: 5848041. DOI: 10.21037/jgo.2017.08.14. View

12.

Pauly M, Tucker L, Szpakowski J, Ready J, Baer D, Hwang J . Incidence of Hepatitis B Virus Reactivation and Hepatotoxicity in Patients Receiving Long-term Treatment With Tumor Necrosis Factor Antagonists. Clin Gastroenterol Hepatol. 2018; 16(12):1964-1973.e1. DOI: 10.1016/j.cgh.2018.04.033. View

13.

Abe M, Mashiba T, Zeniya M, Yamamoto K, Onji M, Tsubouchi H . Present status of autoimmune hepatitis in Japan: a nationwide survey. J Gastroenterol. 2011; 46(9):1136-41. DOI: 10.1007/s00535-011-0421-y. View

14.

Bournia V, Vlachoyiannopoulos P . Subgroups of Sjögren syndrome patients according to serological profiles. J Autoimmun. 2012; 39(1-2):15-26. DOI: 10.1016/j.jaut.2012.03.001. View

15.

Takahashi A, Abe K, Saito R, Iwadate H, Okai K, Katsushima F . Liver dysfunction in patients with systemic lupus erythematosus. Intern Med. 2013; 52(13):1461-5. DOI: 10.2169/internalmedicine.52.9458. View

16.

Takeuchi A, Haraoka H, Hashimoto T . Increased serum alkaline phosphatase activity in Behçet's disease. Clin Exp Rheumatol. 1989; 7(6):619-21. View

17.

Parisis D, Chivasso C, Perret J, Soyfoo M, Delporte C . Current State of Knowledge on Primary Sjögren's Syndrome, an Autoimmune Exocrinopathy. J Clin Med. 2020; 9(7). PMC: 7408693. DOI: 10.3390/jcm9072299. View

18.

Tanaka A, Notohara K . Immunoglobulin G4 (IgG4)-related autoimmune hepatitis and IgG4-hepatopathy: A histopathological and clinical perspective. Hepatol Res. 2021; 51(8):850-859. DOI: 10.1111/hepr.13683. View

19.

Rigamonti C, Shand L, Feudjo M, Bunn C, Black C, Denton C . Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut. 2005; 55(3):388-94. PMC: 1856066. DOI: 10.1136/gut.2005.075002. View

20.

Assassi S, Fritzler M, Arnett F, Norman G, Shah K, Gourh P . Primary biliary cirrhosis (PBC), PBC autoantibodies, and hepatic parameter abnormalities in a large population of systemic sclerosis patients. J Rheumatol. 2009; 36(10):2250-6. PMC: 2885441. DOI: 10.3899/jrheum.090340. View